CA2690541A1 - Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same - Google Patents

Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same Download PDF

Info

Publication number
CA2690541A1
CA2690541A1 CA2690541A CA2690541A CA2690541A1 CA 2690541 A1 CA2690541 A1 CA 2690541A1 CA 2690541 A CA2690541 A CA 2690541A CA 2690541 A CA2690541 A CA 2690541A CA 2690541 A1 CA2690541 A1 CA 2690541A1
Authority
CA
Canada
Prior art keywords
biomarkers
metabolite
subject
level
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2690541A
Other languages
English (en)
French (fr)
Inventor
Yun Fu Hu
Costel Chirila
Danny Alexander
Michael Milburn
Matthew W. Mitchell
Walter Gall
Kay Lawton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolon Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2690541A1 publication Critical patent/CA2690541A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
CA2690541A 2007-07-17 2008-07-17 Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same Abandoned CA2690541A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95028607P 2007-07-17 2007-07-17
US60/950,286 2007-07-17
US3762808P 2008-03-18 2008-03-18
US61/037,628 2008-03-18
PCT/US2008/008756 WO2009014639A2 (en) 2007-07-17 2008-07-17 Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same

Publications (1)

Publication Number Publication Date
CA2690541A1 true CA2690541A1 (en) 2009-01-29

Family

ID=40282019

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2690541A Abandoned CA2690541A1 (en) 2007-07-17 2008-07-17 Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same

Country Status (9)

Country Link
US (5) US8187830B2 (enExample)
EP (1) EP2164977B1 (enExample)
JP (3) JP5701601B2 (enExample)
AU (1) AU2008279778B2 (enExample)
BR (1) BRPI0815095B1 (enExample)
CA (1) CA2690541A1 (enExample)
ES (1) ES2443540T3 (enExample)
MX (3) MX341954B (enExample)
WO (1) WO2009014639A2 (enExample)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2008108B1 (en) * 2006-03-24 2010-12-29 Metanomics GmbH MEANS AND METHOD FOR PREDICTING DIABETES type II
EP2053395A4 (en) * 2006-08-04 2010-04-21 Ajinomoto Kk METABOLIC SYNDROME EVALUATION PROCEDURES, METABOLIC SYNDROME EVALUATION DEVICE, METABOLIC SYNDROME EVALUATION PROCEDURES, METABOLIC SYNDROME EVALUATION SYSTEM, METABOLIC SYNDROME EVALUATION PROGRAM AND RECORDING MEDIUM AND METHOD FOR SEARCHING FOR A PROPHYLACTIC / soothing SUBSTANCE FOR METABOLIC SYNDROME
US9867530B2 (en) 2006-08-14 2018-01-16 Volcano Corporation Telescopic side port catheter device with imaging system and method for accessing side branch occlusions
EP2172775A4 (en) * 2007-06-25 2010-12-01 Ajinomoto Kk METHOD OF EVALUATING VISCERAL GREASE ACCUMULATION
US9622706B2 (en) 2007-07-12 2017-04-18 Volcano Corporation Catheter for in vivo imaging
US10219780B2 (en) 2007-07-12 2019-03-05 Volcano Corporation OCT-IVUS catheter for concurrent luminal imaging
US9596993B2 (en) 2007-07-12 2017-03-21 Volcano Corporation Automatic calibration systems and methods of use
JP5701601B2 (ja) * 2007-07-17 2015-04-15 メタボロン インコーポレイテッド 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法
EP2209001A4 (en) * 2007-10-25 2010-10-27 Ajinomoto Kk METHOD FOR ASSESSING STROKEN GLUCOSE TOLERANCE
EP2227689B1 (en) * 2007-11-02 2012-12-26 Metabolon, Inc. Biomarkers for fatty liver disease and methods using the same
WO2009092068A1 (en) 2008-01-18 2009-07-23 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
CN102066943A (zh) * 2008-04-09 2011-05-18 B.R.A.H.M.S有限公司 用于预测受损峰值耗氧量的内皮素1原
US20100222315A1 (en) * 2008-09-24 2010-09-02 Harbor BioSciencs, Inc. Patient populations and treatment methods
JP5393798B2 (ja) * 2008-10-20 2014-01-22 リポサイエンス，インコーポレイテッド リポタンパク質インスリン抵抗性指数、ならびに同一物を生成するための関連する方法、システムおよびコンピュータプログラム
EP2405806A4 (en) 2009-03-10 2014-01-22 Univ Duke PROGNOSIS OF CORONARY ARTERY DISEASE AND THE RISK OF CARDIOVASCULAR EVENTS
WO2010114897A1 (en) * 2009-03-31 2010-10-07 Metabolon, Inc. Biomarkers related to insulin resistance and methods using the same
AU2010247750B2 (en) 2009-05-11 2016-09-22 Berg Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CN102625932A (zh) * 2009-09-08 2012-08-01 诺达利蒂公司 细胞网络分析
JP5787339B2 (ja) * 2009-12-28 2015-09-30 学校法人福岡大学 糖尿病前症の検査方法
CA2793735A1 (en) * 2010-03-23 2011-09-29 M. Daniel Raftery Early detection of recurrent breast cancer using metabolite profiling
WO2011155518A1 (ja) 2010-06-08 2011-12-15 カルピス株式会社 脂質代謝改善剤
MX361944B (es) 2010-07-23 2018-12-19 President And Fellows Of Harvard College Star Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales.
EP2596116A4 (en) 2010-07-23 2014-03-19 Harvard College METHOD FOR DETECTING AUTOIMMUNE OR AUTOIMMUNE DISORDERS OR SUFFERING
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
WO2012012709A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting cardiovascular diseases or conditions
KR20130041962A (ko) 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 식작용 세포를 사용하여 질환 또는 상태를 검출하는 방법
US20130126725A1 (en) * 2010-07-30 2013-05-23 Technische Universität Graz Analyses of Analytes by Mass Spectrometry with Values in at Least 3 Dimensions
WO2012058298A1 (en) * 2010-10-26 2012-05-03 Mayo Foundation For Medical Education And Research Biomarkers of reduced insulin action
CN103403548A (zh) * 2010-12-23 2013-11-20 梅坦诺米克斯保健有限公司 用于预测糖尿病的工具和方法
US11141063B2 (en) 2010-12-23 2021-10-12 Philips Image Guided Therapy Corporation Integrated system architectures and methods of use
US11040140B2 (en) 2010-12-31 2021-06-22 Philips Image Guided Therapy Corporation Deep vein thrombosis therapeutic methods
WO2012116074A1 (en) * 2011-02-22 2012-08-30 Mayo Foundation For Medical Education And Research Biomarkers of insulin sensitivity
KR101933732B1 (ko) 2011-04-04 2018-12-28 버그 엘엘씨 중추 신경 시스템 종양들의 치료 방법
JP6260275B2 (ja) 2011-06-30 2018-01-17 味の素株式会社 脂肪肝の評価方法、脂肪肝評価装置、脂肪肝評価方法、脂肪肝評価プログラム、脂肪肝評価システム、および端末装置
EP3527990A1 (en) * 2011-07-28 2019-08-21 metanomics GmbH Use of sm_sphingomyelin (d18:1, c23:1) as a marker for heart failure
WO2013033592A1 (en) 2011-08-31 2013-03-07 Volcano Corporation Optical-electrical rotary joint and methods of use
WO2013039898A1 (en) * 2011-09-14 2013-03-21 Metabolon, Inc. Biomarkers related to insulin resistance and methods using the same
WO2013122469A2 (en) * 2012-02-17 2013-08-22 Rijksuniversiteit Groningen Prediction of the efficacy of a medicament on renal or cardiovascular clinical outcomes
EP2642296A1 (en) * 2012-03-22 2013-09-25 Nestec S.A. p-Cresol sulphate as biomarker for healthy ageing
EP2642293A1 (en) * 2012-03-22 2013-09-25 Nestec S.A. 9-oxo-octadecadienoic acid (9-oxo-HODE)as as biomarker for healthy ageing
EP2642294A1 (en) * 2012-03-22 2013-09-25 Nestec S.A. Phenylacetylglutamine as biomarker for healthy ageing
EP2642295A1 (en) 2012-03-22 2013-09-25 Nestec S.A. 1-O-alkyl-2-acylglycerophosphocholine (PC-O) 40:1 as biomarker for healthy ageing
EP2642297A1 (en) * 2012-03-22 2013-09-25 Nestec S.A. Hydroxy-sphingomyelin 22:1 as biomarker for healthy ageing
BR112014030243B1 (pt) * 2012-06-05 2022-07-05 Société Des Produits Nestlé S.A Métodos para diagnosticar doença valvular crônica
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
BR112014031414A2 (pt) 2012-06-15 2017-06-27 Stylli Harry métodos de detectar doenças ou condições utilizando células doentes circulantes
SG11201408385TA (en) 2012-06-15 2015-01-29 Harry Stylli Methods of detecting diseases or conditions
JP6282642B2 (ja) 2012-06-27 2018-02-21 メタノミクス ヘルス ゲーエムベーハー 糖尿病薬を同定する方法
EP2883058B1 (en) * 2012-08-13 2018-01-03 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Biomarkers for type 2 diabetes
US20140324460A1 (en) * 2012-09-26 2014-10-30 Health Diagnostic Laboratory, Inc. Method for determining and managing total cardiodiabetes risk
US9478940B2 (en) 2012-10-05 2016-10-25 Volcano Corporation Systems and methods for amplifying light
US9307926B2 (en) 2012-10-05 2016-04-12 Volcano Corporation Automatic stent detection
US9292918B2 (en) 2012-10-05 2016-03-22 Volcano Corporation Methods and systems for transforming luminal images
US9367965B2 (en) 2012-10-05 2016-06-14 Volcano Corporation Systems and methods for generating images of tissue
US9286673B2 (en) 2012-10-05 2016-03-15 Volcano Corporation Systems for correcting distortions in a medical image and methods of use thereof
US10568586B2 (en) 2012-10-05 2020-02-25 Volcano Corporation Systems for indicating parameters in an imaging data set and methods of use
US9858668B2 (en) 2012-10-05 2018-01-02 Volcano Corporation Guidewire artifact removal in images
US11272845B2 (en) 2012-10-05 2022-03-15 Philips Image Guided Therapy Corporation System and method for instant and automatic border detection
US10070827B2 (en) 2012-10-05 2018-09-11 Volcano Corporation Automatic image playback
US9324141B2 (en) 2012-10-05 2016-04-26 Volcano Corporation Removal of A-scan streaking artifact
US20140100454A1 (en) 2012-10-05 2014-04-10 Volcano Corporation Methods and systems for establishing parameters for three-dimensional imaging
US9840734B2 (en) 2012-10-22 2017-12-12 Raindance Technologies, Inc. Methods for analyzing DNA
JP6322210B2 (ja) 2012-12-13 2018-05-09 ボルケーノ コーポレイション 標的化された挿管のためのデバイス、システム、および方法
JP6785554B2 (ja) 2012-12-20 2020-11-18 ボルケーノ コーポレイション 平滑遷移カテーテル
WO2014107287A1 (en) 2012-12-20 2014-07-10 Kemp Nathaniel J Optical coherence tomography system that is reconfigurable between different imaging modes
US10939826B2 (en) 2012-12-20 2021-03-09 Philips Image Guided Therapy Corporation Aspirating and removing biological material
JP2016506276A (ja) 2012-12-20 2016-03-03 ジェレミー スティガール， 血管内画像の位置の特定
US11406498B2 (en) 2012-12-20 2022-08-09 Philips Image Guided Therapy Corporation Implant delivery system and implants
US10942022B2 (en) 2012-12-20 2021-03-09 Philips Image Guided Therapy Corporation Manual calibration of imaging system
WO2014099763A1 (en) 2012-12-21 2014-06-26 Jason Spencer System and method for graphical processing of medical data
EP2934280B1 (en) 2012-12-21 2022-10-19 Mai, Jerome Ultrasound imaging with variable line density
US10420530B2 (en) 2012-12-21 2019-09-24 Volcano Corporation System and method for multipath processing of image signals
EP2934653B1 (en) 2012-12-21 2018-09-19 Douglas Meyer Rotational ultrasound imaging catheter with extended catheter body telescope
US9486143B2 (en) 2012-12-21 2016-11-08 Volcano Corporation Intravascular forward imaging device
US9612105B2 (en) 2012-12-21 2017-04-04 Volcano Corporation Polarization sensitive optical coherence tomography system
JP2016508233A (ja) 2012-12-21 2016-03-17 ナサニエル ジェイ． ケンプ， 光学スイッチを用いた電力効率のよい光学バッファリング
US10058284B2 (en) 2012-12-21 2018-08-28 Volcano Corporation Simultaneous imaging, monitoring, and therapy
WO2014100530A1 (en) 2012-12-21 2014-06-26 Whiseant Chester System and method for catheter steering and operation
US9383263B2 (en) 2012-12-21 2016-07-05 Volcano Corporation Systems and methods for narrowing a wavelength emission of light
ES2987582T3 (es) * 2013-01-31 2024-11-15 Metabolon Inc Biomarcadores relacionados con la progresión de la resistencia a la Insulina y métodos que lo utilizan
WO2014118634A1 (en) * 2013-01-31 2014-08-07 Eustache Paramithiotis Type 2 diabetes biomarkers and uses thereof
DE112014000822T5 (de) * 2013-02-14 2015-10-29 Metanomics Health Gmbh Mittel und Verfahren zur Beurteilung der Qualität einer biologischen Probe
US10226597B2 (en) 2013-03-07 2019-03-12 Volcano Corporation Guidewire with centering mechanism
CN113705586A (zh) 2013-03-07 2021-11-26 飞利浦影像引导治疗公司 血管内图像中的多模态分割
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
US11154313B2 (en) 2013-03-12 2021-10-26 The Volcano Corporation Vibrating guidewire torquer and methods of use
EP2967391A4 (en) 2013-03-12 2016-11-02 Donna Collins SYSTEMS AND METHOD FOR THE DIAGNOSIS OF CORONARY MICROVASCULAR DISEASES
US20140278121A1 (en) * 2013-03-13 2014-09-18 Robust for Life, Inc. Systems and methods for network-based calculation and reporting of metabolic risk
US11026591B2 (en) 2013-03-13 2021-06-08 Philips Image Guided Therapy Corporation Intravascular pressure sensor calibration
JP6339170B2 (ja) 2013-03-13 2018-06-06 ジンヒョン パーク 回転式血管内超音波装置から画像を生成するためのシステム及び方法
US9301687B2 (en) 2013-03-13 2016-04-05 Volcano Corporation System and method for OCT depth calibration
CN105208947B (zh) 2013-03-14 2018-10-12 火山公司 具有回声特性的过滤器
US12343198B2 (en) 2013-03-14 2025-07-01 Philips Image Guided Therapy Corporation Delivery catheter having imaging capabilities
US10292677B2 (en) 2013-03-14 2019-05-21 Volcano Corporation Endoluminal filter having enhanced echogenic properties
US10219887B2 (en) 2013-03-14 2019-03-05 Volcano Corporation Filters with echogenic characteristics
SG11201508272YA (en) 2013-04-08 2015-11-27 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
CA2921530A1 (en) 2013-07-18 2015-01-22 True Health Diagnostics, Llc Method of determination of risk of 2 hour blood glucose equal to or greater than 140 mg/dl
HUE050060T2 (hu) 2013-09-04 2020-11-30 Berg Llc Eljárások rák kezelésére koenzim Q10 folyamatos infúziójával
GB2524230A (en) * 2014-02-14 2015-09-23 Asda Stores Ltd Transaction processing system and transaction processing method
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
US20170316176A1 (en) * 2014-12-25 2017-11-02 Hitachi, Ltd. Device for analyzing insulin secretion ability, system for analyzing insulin secretion ability provided with same, and method for analyzing insulin secretion ability
MX388989B (es) * 2015-01-09 2025-03-11 Global Genomics Group Llc Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerótica.
US10451641B2 (en) 2015-03-13 2019-10-22 Duke University Compositions and methods for metabolic profiling in subjects with heart failure with preserved ejection fraction
JP6051258B2 (ja) * 2015-04-15 2016-12-27 ライオン株式会社 脂質異常症への罹患しやすさを試験する方法
KR101795689B1 (ko) * 2015-04-30 2017-11-30 경희대학교 산학협력단 혈관 협착 질환 진단용 마커 및 이의 용도
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
WO2018094204A1 (en) * 2016-11-17 2018-05-24 Arivale, Inc. Determining relationships between risks for biological conditions and dynamic analytes
US11881311B1 (en) 2017-02-17 2024-01-23 BioAge Labs, Inc. Survival prediction using metabolomic profiles
JP2018141728A (ja) * 2017-02-28 2018-09-13 トヨタ自動車株式会社 生活習慣病の診断方法
AU2018371776A1 (en) * 2017-11-22 2020-05-28 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating obesity
US20200041496A1 (en) * 2018-08-01 2020-02-06 Joshua Health Care LLC Methods for Identifying and Treating Mammalian Subjects with Insulin Resistance
JP7189537B2 (ja) * 2019-06-27 2022-12-14 サンスター株式会社 血液試料の酸化ｈｄｌ量の反映値を測定する工程を含む、測定方法
EP3997980A4 (en) * 2019-07-08 2023-06-21 Shimadzu Corporation TRANSPLANT ORGAN FUNCTIONAL EVALUATION METHOD, TRANSPLANT ORGAN FUNCTIONAL EVALUATION PROGRAM AND TRANSPLANT ORGAN FUNCTIONAL EVALUATION DEVICE
US20240085432A1 (en) * 2019-10-11 2024-03-14 The Regents Of The University Of California Metabolic profile screening for gestational diabetes
EP4100541A4 (en) * 2020-02-05 2024-05-22 The Cleveland Clinic Foundation Disease detection and treatment based on phenylacetyl glutamine levels
CN113866284B (zh) * 2020-06-30 2023-09-05 上海脉示生物技术有限公司 一组用于心力衰竭诊断的肠道微生物代谢标志物及其应用
CN112684064B (zh) * 2020-12-08 2022-05-17 安徽农业大学 用于筛选抗应激胁迫肉羊的血清代谢标志物及其应用
WO2022133034A1 (en) * 2020-12-16 2022-06-23 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor
CN113325117B (zh) * 2021-06-25 2022-07-15 中国医学科学院北京协和医院 一组生物标记物在制备预测静脉内平滑肌瘤病进展的试剂盒中的应用
CN117741023A (zh) * 2021-11-30 2024-03-22 江苏品生医疗科技集团有限公司 预测受试者患有糖尿病的可能性的标记物及其应用
WO2023147522A1 (en) * 2022-01-28 2023-08-03 GATC Health Corp Biomarkers for early detection of diabetes
CN114965733B (zh) * 2022-04-07 2023-12-01 中国人民解放军总医院第一医学中心 结直肠进展期腺瘤诊断代谢标志物组合及其应用
WO2025019706A1 (en) * 2023-07-19 2025-01-23 Ahara Corporation Systems and methods for generating a nutrition program
JP2025112741A (ja) * 2024-01-22 2025-08-01 富士フイルム株式会社 情報管理装置及び情報管理装置の作動方法並びに情報管理プログラム
CN119846232B (zh) * 2025-01-21 2025-10-03 宁夏农林科学院动物科学研究所(宁夏草畜工程技术研究中心) 一种早期诊断奶牛隐性乳房炎的生物标志物组合及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5367052A (en) * 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
EP0825258A4 (en) * 1996-02-20 2001-12-05 Kyowa Hakko Kogyo Kk METHOD OF DETERMINING 1,5-ANHYDROGLUCITOL
JP2938048B1 (ja) * 1998-06-30 1999-08-23 技術研究組合医療福祉機器研究所 代謝機能測定装置
US6140067A (en) * 1999-04-30 2000-10-31 Mitokor Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
JP3975279B2 (ja) * 1999-11-01 2007-09-12 旭化成ファーマ株式会社 糖尿病予備群の検査方法
US7329489B2 (en) * 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US20020009740A1 (en) * 2000-04-14 2002-01-24 Rima Kaddurah-Daouk Methods for drug discovery, disease treatment, and diagnosis using metabolomics
PL365135A1 (en) * 2000-08-07 2004-12-27 Ranbaxy Signature Llc Liquid formulation of metformin
CN1533435A (zh) * 2001-06-01 2004-09-29 克林杰尼克斯公司 用于诊断及治疗胰岛素抗性及相关病症之方法和试剂
US7425545B2 (en) * 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
JP4100673B2 (ja) * 2001-12-07 2008-06-11 日本化薬株式会社 肝糖放出の検査方法
JP2003204800A (ja) * 2002-01-15 2003-07-22 Sumitomo Pharmaceut Co Ltd 糖代謝異常疾患マーカーおよびその利用
US20040101874A1 (en) * 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
AU2003246644A1 (en) * 2002-07-08 2004-01-23 Genova, Ltd. Secreted peptides
JP2005006645A (ja) * 2003-05-22 2005-01-13 Sumitomo Chemical Co Ltd インスリン応答性の評価方法
US7648825B2 (en) * 2003-06-20 2010-01-19 University Of Florida Research Foundation, Inc. Biomarkers for differentiating between type 1 and type 2 diabetes
US7345142B2 (en) * 2004-01-27 2008-03-18 Compugen Ltd. Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease
JP4547173B2 (ja) * 2004-03-17 2010-09-22 シスメックス株式会社 糖尿病診療支援システム
JP4533042B2 (ja) * 2004-08-25 2010-08-25 裕 笹川 糖尿病および糖代謝異常を判断する方法
US20080261317A1 (en) * 2004-09-07 2008-10-23 Fifer Michael A Methods of Detecting Myocardial Ischemia and Myocardial Infarction
JP4522222B2 (ja) * 2004-10-22 2010-08-11 扶桑薬品工業株式会社 血中脂肪酸濃度測定による心疾患の早期診断方法
WO2006063733A1 (en) * 2004-12-14 2006-06-22 F.Hoffmann-La Roche Ag Cd99 as target/marker for insulin resistance
US20070026458A1 (en) * 2004-12-17 2007-02-01 Entelos, Inc. Assessing insulin resistance using biomarkers
WO2006073195A1 (ja) * 2005-01-07 2006-07-13 Biomarker Science Co., Ltd 糖尿病の予知・診断方法および糖尿病予知・診断用キット
FR2890079B1 (fr) * 2005-08-26 2007-11-30 Alain Rambach Detection des salmonelles lactose +
WO2007038670A2 (en) * 2005-09-30 2007-04-05 Perlegen Sciences, Inc. Methods and compositions for screening and treatment of disorders of blood glucose regulation
US20070218519A1 (en) * 2005-10-11 2007-09-20 Tethys Bioscience, Inc. Diabetes-associated markers and methods of use thereof
JP2007127423A (ja) * 2005-10-31 2007-05-24 Toray Ind Inc ３−ヒドロキシ酪酸の測定方法およびキット
EP2008108B1 (en) * 2006-03-24 2010-12-29 Metanomics GmbH MEANS AND METHOD FOR PREDICTING DIABETES type II
WO2008118413A2 (en) * 2007-03-26 2008-10-02 Bg Medicine, Inc. Methods for detecting coronary artery disease
JP5701601B2 (ja) * 2007-07-17 2015-04-15 メタボロン インコーポレイテッド 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法
WO2010114897A1 (en) * 2009-03-31 2010-10-07 Metabolon, Inc. Biomarkers related to insulin resistance and methods using the same
CN103403548A (zh) * 2010-12-23 2013-11-20 梅坦诺米克斯保健有限公司 用于预测糖尿病的工具和方法

Also Published As

Publication number Publication date
US9250225B2 (en) 2016-02-02
EP2164977A4 (en) 2011-07-27
BRPI0815095A2 (pt) 2017-05-09
WO2009014639A2 (en) 2009-01-29
US20160178620A1 (en) 2016-06-23
MX377928B (es) 2025-03-10
ES2443540T3 (es) 2014-02-19
US10175233B2 (en) 2019-01-08
JP2010537157A (ja) 2010-12-02
HK1142636A1 (en) 2010-12-10
JP5876918B2 (ja) 2016-03-02
US8187830B2 (en) 2012-05-29
US20120208215A1 (en) 2012-08-16
US8546098B2 (en) 2013-10-01
EP2164977A2 (en) 2010-03-24
AU2008279778A1 (en) 2009-01-29
US20130338031A1 (en) 2013-12-19
BRPI0815095B1 (pt) 2021-04-13
JP5701601B2 (ja) 2015-04-15
US8809008B2 (en) 2014-08-19
WO2009014639A3 (en) 2009-03-19
JP2015064362A (ja) 2015-04-09
MX2010000414A (es) 2010-04-01
US20150005195A1 (en) 2015-01-01
US20090155826A1 (en) 2009-06-18
JP2016102797A (ja) 2016-06-02
AU2008279778B2 (en) 2014-09-18
EP2164977B1 (en) 2013-10-30
MX341954B (es) 2016-09-08

Similar Documents

Publication Publication Date Title
AU2008279778B2 (en) Method for Determining Insulin Sensitivity with Biomarkers
US9910047B2 (en) Biomarkers related to insulin resistance progression and methods using the same
US20120122981A1 (en) Biomarkers Related to Insulin Resistance and Methods using the Same
ES2358454T3 (es) Medios y método para predecir diabetes tipo ii.
JP6158186B2 (ja) インスリン抵抗性に関連するバイオマーカーおよびそれを使用する方法
AU2016206265B2 (en) Method for Determining Insulin Sensitivity with Biomarkers
AU2014216035A1 (en) Method for Determining Insulin Sensitivity with Biomarkers
HK1142636B (en) Biomarkers for pre-diabetes and methods using the same
CN119470683A (zh) 预测会否成为aclf的生物标志物、系统及其应用
HK1217516B (en) Biomarkers related to insulin resistance progression and methods using the same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130426

FZDE Discontinued

Effective date: 20180613